Literature DB >> 12072654

Interstitial cystitis: an update.

Frank Oberpenning1, Arndt van Ophoven, Lothar Hertle.   

Abstract

PURPOSE OF REVIEW: Interstitial cystitis is a chronically progressive, severely debilitating, heterogeneous syndrome affecting the urinary bladder, mainly associated with urgency, frequency and pain. Though known for over a century, its etiology is poorly understood and universally effective treatments are lacking. This review focuses on recently published literature on the disorder. RECENT
FINDINGS: Appropriate diagnostic tests for interstitial cystitis remain uncertain. The diagnostic criteria developed by the US National Institutes of Health represent research definitions which are subject to controversial debate for their overenthusiastic clinical application. The diagnosis is made clinically and by cystoscopy with hydrodistention and sometimes biopsy when other pathologies have been excluded. In symptomatic patients, glomerulations upon bladder distension are indicative but not pathognomonic for nonulcerative interstitial cystitis. Patients with ulcerative disease represent a separate subgroup with distinct characteristics and treatment implications. The role of bladder permeability tests remains controversial. Promising noninvasive markers for interstitial cystitis have been described but are not yet clinically available. Validated symptom scores are appropriate to assist in diagnostics and to monitor disease course and treatment efficacy. Lately investigated hypotheses for causative factors include occult or resistant microorganisms, urothelial hyperpermeability, neurogenic or hormonal pathomechanisms, and mast cell activation. Increasing evidence for a genetic susceptibility is emerging.
SUMMARY: Among the multitude of oral, intravesical, interventional and complementary treatments suggested few studies have high levels of evidence. Newly proposed agents must await further controlled studies. Treatment remains empiric until radical surgical procedures should ultimately be considered for severe refractory cases.

Entities:  

Mesh:

Year:  2002        PMID: 12072654     DOI: 10.1097/00042307-200207000-00011

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  6 in total

1.  Somatic Comorbidity in Women with Overactive Bladder Syndrome.

Authors:  Daniel Altman; Anastasia N Iliadou; Cecilia Lundholm; Ian Milsom; Nancy L Pedersen
Journal:  J Urol       Date:  2016-02-19       Impact factor: 7.450

2.  Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis.

Authors:  Daniele Porru; Fabio Leva; Alberto Parmigiani; Davide Barletta; Dimitrios Choussos; Barbara Gardella; Maria Diletta Daccò; Rossella Elena Nappi; Massimo Allegri; Carmine Tinelli; Carlo Maria Bianchi; Arsenio Spinillo; Bruno Rovereto
Journal:  Int Urogynecol J       Date:  2011-09-09       Impact factor: 2.894

3.  Cyclical estrogen and free radical damage to the rabbit urinary bladder.

Authors:  Alexandra Rehfuss; Catherine Schuler; Christina Maxemous; Robert E Leggett; Robert M Levin
Journal:  Int Urogynecol J       Date:  2009-12-03       Impact factor: 2.894

Review 4.  Mast cells: an expanding pathophysiological role from allergy to other disorders.

Authors:  Preet Anand; Baldev Singh; Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-06       Impact factor: 3.000

5.  New insights into the mechanism of the down-regulation of mast cells in the treatment of interstitial cystitis: possible role of siglecs.

Authors:  Tack Lee
Journal:  Int Neurourol J       Date:  2011-06-30       Impact factor: 2.835

Review 6.  Genes, molecules and patients--emerging topics to guide clinical pain research.

Authors:  Shafaq Sikandar; Ryan Patel; Sital Patel; Sanam Sikander; David L H Bennett; Anthony H Dickenson
Journal:  Eur J Pharmacol       Date:  2013-03-13       Impact factor: 4.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.